Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab Ozogamicin + Rituximab vs Investigator's Choice in Relapsed/Refractory Follicular Lymphoma
NCT00562965Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Nov 2007
- Primary completion
- Apr 2011
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of inotuzumab ozogamicin in follicular lymphoma (FL), sponsored by Pfizer. Started Nov 2007; status: terminated.
02
Drugs
inotuzumab ozogamicin
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00562965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00562965.